CA
NZ
UK
US
AU
IND
Last update at 2025-05-09T16:39:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Knight Therapeutics Inc. announces voting results from the Annual General Meeting
Wed 07 May 25, 09:10 PMKnight Therapeutics Announces Relaunch of ONICIT® in Brazil and Mexico
Wed 07 May 25, 11:30 AMNotice of Knight Therapeutics' First Quarter 2025 Results Conference Call
Thu 01 May 25, 11:30 AMKnight to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference
Tue 29 Apr 25, 08:30 PMKnight Therapeutics Announces Launch of Minjuvi® (tafasitamab) in Mexico
Wed 26 Mar 25, 11:30 AMKnight Therapeutics Reports Fourth Quarter and Year-End 2024 Results
Thu 20 Mar 25, 11:30 AMNotice of Knight Therapeutics' Fourth Quarter and Year End 2024 Results Conference Call
Thu 13 Mar 25, 11:30 AMKnight Therapeutics to Acquire Paladin
Tue 11 Mar 25, 10:45 AM| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Income before tax | -21.98800M | -43.96000M | 6.69M | 32.09M | 22.78M |
| Minority interest | - | - | - | - | - |
| Net income | -16.83500M | -29.89200M | 15.68M | 31.76M | 14.52M |
| Selling general administrative | 37.41M | 40.15M | 37.16M | 38.84M | 24.46M |
| Selling and marketing expenses | 46.28M | 48.47M | 37.22M | 35.59M | 7.79M |
| Gross profit | 107.61M | 138.06M | 115.41M | 81.69M | 26.92M |
| Reconciled depreciation | - | - | - | - | - |
| Ebit | 6.43M | -2.40300M | -5.32200M | -3.43700M | 13.99M |
| Ebitda | 56.82M | 60.22M | 42.59M | 28.64M | 18.26M |
| Depreciation and amortization | 50.40M | 62.62M | 47.91M | 32.08M | 4.27M |
| Non operating income net other | - | - | - | - | - |
| Operating income | 6.43M | -2.40300M | -5.32200M | -3.43700M | 13.99M |
| Other operating expenses | 321.77M | 310.62M | 256.31M | 229.52M | 60.12M |
| Interest expense | 12.49M | 6.60M | 3.62M | 3.40M | 1.01M |
| Tax provision | - | - | - | - | - |
| Interest income | - | - | - | - | - |
| Net interest income | - | - | - | - | - |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -5.15300M | -14.06800M | -8.98500M | 0.33M | 4.75M |
| Total revenue | 328.20M | 293.56M | 243.48M | 199.52M | 47.46M |
| Total operating expenses | 101.19M | 155.12M | 128.24M | 111.69M | 39.58M |
| Cost of revenue | 220.59M | 155.50M | 128.07M | 117.83M | 20.54M |
| Total other income expense net | -28.41400M | -41.55700M | 12.01M | 35.52M | 8.80M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | - | - | - | - | - |
| Net income applicable to common shares | - | - | - | - | - |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 945.49M | 1054.84M | 991.89M | 1039.68M | 1305.30M |
| Intangible assets | 289.96M | 338.78M | 350.30M | 156.55M | 173.37M |
| Earning assets | - | - | - | - | - |
| Other current assets | 20.63M | 1.70M | 4.51M | 4.75M | 85.01M |
| Total liab | 198.62M | 228.98M | 149.87M | 153.44M | 390.20M |
| Total stockholder equity | 746.87M | 825.86M | 842.02M | 886.24M | 810.73M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 7.90M | 15.01M | 11.72M | 15.90M | 225.63M |
| Common stock | 540.05M | 599.05M | 628.85M | 694.35M | 723.83M |
| Capital stock | - | 599.05M | 628.85M | 694.35M | 723.83M |
| Retained earnings | 150.89M | 161.75M | 191.65M | 174.54M | 52.25M |
| Other liab | - | - | 31.89M | 36.83M | 29.56M |
| Good will | 79.84M | 82.27M | 75.40M | 77.72M | 88.26M |
| Other assets | - | 15.60M | 57.05M | 75.49M | 151.97M |
| Cash | 58.76M | 71.68M | 85.96M | 229.59M | 169.27M |
| Cash and equivalents | - | 0.30M | 9.03M | 2.58M | 5.34M |
| Total current liabilities | 114.03M | 141.32M | 105.30M | 114.06M | 350.80M |
| Current deferred revenue | 1.18M | - | - | 14.61M | 39.85M |
| Net debt | 10.33M | 6.02M | -45.00500M | -173.40400M | -107.08900M |
| Short term debt | 19.58M | 20.25M | 28.28M | 53.65M | 52.34M |
| Short long term debt | - | 17.67M | 26.66M | 51.77M | 50.56M |
| Short long term debt total | 69.09M | 77.70M | 40.96M | 56.19M | 62.18M |
| Other stockholder equity | 25.99M | 23.78M | 21.89M | 18.85M | 17.25M |
| Property plant equipment | - | 22.63M | 29.94M | 26.16M | 29.05M |
| Total current assets | 365.12M | 395.62M | 307.32M | 554.64M | 698.22M |
| Long term investments | - | 158.02M | 178.95M | 174.84M | 259.72M |
| Net tangible assets | - | - | 416.32M | 651.97M | 549.10M |
| Short term investments | 95.66M | 119.54M | 77.03M | 181.75M | 261.35M |
| Net receivables | 98.23M | 110.20M | 67.41M | 82.04M | 111.73M |
| Long term debt | - | 52.40M | 9.27M | 0.00000M | 5.02M |
| Inventory | 91.83M | 92.49M | 72.40M | 56.51M | 70.87M |
| Accounts payable | 85.37M | 106.06M | 65.31M | 44.51M | 72.83M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 29.95M | 41.27M | -0.37600M | -1.50300M | 17.41M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | 694.35M | 723.83M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 7.77M | 48.20M | 47.93M | 47.33M | 52.69M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 580.38M | 659.22M | 684.57M | 485.04M | 607.08M |
| Capital lease obligations | - | 7.63M | 5.03M | 4.42M | 6.60M |
| Long term debt total | - | 57.45M | 12.68M | 2.54M | 9.83M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Investments | - | - | - | - | - |
| Change to liabilities | - | - | - | - | - |
| Total cashflows from investing activities | - | - | - | - | - |
| Net borrowings | - | - | - | - | - |
| Total cash from financing activities | -71.12300M | 1.76M | -78.31000M | -29.23300M | -62.79500M |
| Change to operating activities | - | - | - | - | - |
| Net income | -16.83500M | -29.89200M | 15.68M | 31.76M | 18.03M |
| Change in cash | -12.91800M | -14.28400M | -143.62900M | 55.32M | -70.51700M |
| Begin period cash flow | 71.68M | 85.96M | 229.59M | 174.27M | 244.78M |
| End period cash flow | 58.76M | 71.68M | 85.96M | 229.59M | 174.27M |
| Total cash from operating activities | 28.49M | 40.48M | 44.62M | -12.20500M | 4.60M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 50.40M | 62.62M | 47.91M | 32.08M | 4.27M |
| Other cashflows from investing activities | - | - | - | - | - |
| Dividends paid | - | - | - | - | - |
| Change to inventory | 0.70M | -11.42800M | -17.18800M | 9.71M | 8.15M |
| Change to account receivables | 5.58M | -26.41800M | 8.59M | 20.11M | -10.40300M |
| Sale purchase of stock | -53.47900M | -30.06900M | -64.41500M | -36.78700M | -54.83800M |
| Other cashflows from financing activities | -2.85100M | 52.12M | 9.72M | 25.41M | 0.66M |
| Change to netincome | - | - | - | - | - |
| Capital expenditures | 9.96M | 25.82M | 224.18M | 20.67M | 2.95M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | -28.01300M | -9.98900M | 0.63M | -21.60700M | -12.19900M |
| Stock based compensation | 2.33M | 1.89M | 3.04M | 1.95M | 2.14M |
| Other non cash items | 29.74M | 32.98M | -15.00800M | -54.37100M | -8.55800M |
| Free cash flow | 18.54M | 14.66M | -179.56500M | -32.87300M | 1.65M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
| Company | Change (CAD) | Price (CAD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | ||
|---|---|---|---|---|---|---|---|---|
| GUD Knight Therapeutics Inc. |
0.04 0.70% | 5.72 | - | - | - | - | ||
| BHC Bausch Health Companies Inc |
-0.14 2.13% | 6.42 | - | 2.23 | 0.50 | 18.74 | 2.56 | 9.13 |
| CURA Curaleaf Holdings Inc. |
-0.05 4.13% | 1.16 | - | 138.89 | 1.62 | 1.66 | 1.73 | 10.18 |
| TLRY Tilray Inc |
-0.01 1.64% | 0.60 | - | 1000.00 | 2.17 | 0.36 | 1.69 | -2.299 |
| CRON Cronos Group Inc |
0.01 0.54% | 2.79 | - | - | 10.18 | 0.70 | 0.02 | -1.9458 |
Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company provides Ladecvina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for vasomotor symptoms; Fibridoner for idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.
3400 de Maisonneuve Boulevard West, Montreal, QC, Canada, H3Z 3B8
| Name | Title | Year Born |
|---|---|---|
| Mr. Jonathan Ross Goodman B.A., BA, L.L.B., LLB, M.B.A., MBA | Exec. Chairman | 1969 |
| Ms. Samira Sakhia BCom, CA, CPA, MBA | Pres, CEO & Director | 1968 |
| Mr. Arvind Utchanah | Chief Financial Officer | NA |
| Ms. Amal Khouri B.Sc., M.B.A. | Chief Bus. Officer | NA |
| Mr. Jeff Martens | Global VP Commercial | NA |
| Mr. Leopoldo Bosano | Vice-Pres of Manufacturing & Operations | NA |
| Ms. Daniela Marino | Global VP of Legal & Compliance | NA |
| Ms. Susan Caroline Emblem | Global VP of HR | NA |
| Ms. Jody Engel | Sr. Director of Bus. Devel. | NA |
| Mr. Jonathan Ross Goodman B.A., L.L.B., M.B.A. | Executive Chairman | 1969 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...